{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:09:54Z","timestamp":1762492194934,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ijcha.2018.10.001","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T19:56:11Z","timestamp":1540410971000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs"],"prefix":"10.1016","volume":"21","author":[{"given":"Francesco","family":"Maranta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Cianfanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Regoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Cianflone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcha.2018.10.001_bb0005","series-title":"Heart Disease and Stroke Statistics'2017 Update: A Report from the American Heart Association","volume":"vol. 135","author":"Benjamin","year":"2017"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0010","series-title":"Global Report on Diabetes","first-page":"88","volume":"978","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2337\/diacare.25.1.43","article-title":"Cause-specific mortality in a population with diabetes: South tees diabetes mortality study","volume":"25","author":"Roper","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0020","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2337\/dc16-0614","article-title":"Risk of cause-specific death in individuals with diabetes: a competing risks analysis","volume":"39","author":"Baena-D\u00edez","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2337\/diacare.8.1.S65","article-title":"Insulin-dependent diabetes mellitus and ischemic heart disease","volume":"8","author":"Barrett-Connor","year":"1985","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0030","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4239\/wjd.v6.i13.1246","article-title":"Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research","volume":"6","author":"Leon","year":"2015","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4169","article-title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"343","author":"Boussageon","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0040","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-015-0269-1","article-title":"Lack of correlation between the optimal glycaemic control and coronary micro vascular dysfunction in patients with diabetes mellitus: a cross sectional study","volume":"14","author":"Valenzuela-Garcia","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0045","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"G\u00e6de","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0050","series-title":"Guidance for Industry Diabetes Mellitus \u2014 Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes","first-page":"1","author":"US FDA","year":"2008"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0055","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0060","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0065","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0070","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0075","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0080","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0085","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/cd16-0067","article-title":"Standards of medical care in diabetes\u20142017 abridged for primary care providers","volume":"35","author":"Recommendations CP","year":"2017","journal-title":"Clin. Diabetes"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-017-0622-7","article-title":"Translating recent results from the cardiovascular outcomes trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)","volume":"16","author":"Schernthaner","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0100","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jacc.2017.04.014","article-title":"Novel diabetes drugs and the cardiovascular specialist","volume":"69","author":"Sattar","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0105","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00125-016-3987-3","article-title":"SGLT2 Inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0110","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a thrifty substrate hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"article-title":"The 2014 Drug Trend Report","year":"2015","author":"Express Scripts","key":"10.1016\/j.ijcha.2018.10.001_bb0115"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0120","series-title":"Per Capita Health Care Spending on Diabetes: 2009\u20132013","first-page":"2009","author":"Health Care Cost Institute, HCCIsue, Health Care Cost Institute","year":"2015"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0125","series-title":"Soc Ital Di Diabetol","first-page":"1","article-title":"Position Statement: Farmaci ipoglicemizzanti, malattie cardiovascolari e renali","author":"Bonora","year":"2017"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0130","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0135","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4103\/2229-3485.167092","article-title":"Common pitfalls in statistical analysis: odds versus risk","volume":"6","author":"Ranganathan","year":"2015","journal-title":"Perspect. Clin. Res."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0140","doi-asserted-by":"crossref","first-page":"g1407","DOI":"10.1136\/bmj.g1407","article-title":"Relative risks versus odds ratios","volume":"348","author":"Sedgwick","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/2229-3485.173773","article-title":"Common pitfalls in statistical analysis: absolute risk reduction, relative risk reduction, and number needed to treat","volume":"7","author":"Ranganathan","year":"2016","journal-title":"Perspect. Clin. Res."},{"year":"2003","series-title":"Essential Medical Statistics","author":"Kirkwood","key":"10.1016\/j.ijcha.2018.10.001_bb0150"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0155","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin Inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0160","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0165","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0170","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0190","doi-asserted-by":"crossref","DOI":"10.2337\/dcS13-2041","article-title":"Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations","volume":"36","author":"Hirshberg","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0195","first-page":"1","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0200","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0205","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular actions of incretin-based therapies","volume":"114","author":"Ussher","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12939-015-0208-5","article-title":"Health care financing and the sustainability of health systems","volume":"14","author":"Liaropoulos","year":"2015","journal-title":"Int. J. Equity Health"},{"key":"10.1016\/j.ijcha.2018.10.001_bb0215","first-page":"1","article-title":"Public spending on health and long-term care: a new set of projections","volume":"6","author":"La Maisonneuve","year":"2013","journal-title":"OECD Econ. Policy Pap."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0175","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0180","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2018.10.001_bb0185","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jacc.2017.07.768","article-title":"Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54","volume":"70","author":"Bonaca","year":"2017","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906718300903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906718300903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:06:58Z","timestamp":1762492018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906718300903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":43,"alternative-id":["S2352906718300903"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2018.10.001","relation":{},"ISSN":["2352-9067"],"issn-type":[{"type":"print","value":"2352-9067"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2018.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}